ArticleTransfusion2025
Supplemental findings of the 2023 National Blood Collection and Utilization Survey.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Routine transfusion of Rh(D)-positive RBCs to Rh(D)-negative patients designated as do not resuscitate conserves Rh(D)-negative red blood cell inventory.Transfusion · 2026Article
- Article
- An audit of platelet transfusions at a tertiary care center: New opportunities for patient blood management with the 2025 AABB/ICTMG platelet guidelines.Transfusion · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe National Blood Collection and Utilization Survey (NBCUS) is conducted biennially to estimate US blood collection and utilization. Supplemental data from the 2023 NBCUS not presented elsewhere are described here.
methodsData on blood donor characteristics, donation deferrals, component costs, transfusion-associated adverse reactions, and use of pathogen-reduced platelets during 2023 were collected from US blood collecting and transfusing facilities. National estimates were produced using weighting and imputation methods.
resultsCompared with 2021, successful blood donations from donors aged 45-64 decreased (11%) in 2023 but still accounted for most donations overall (39%). Donations from donors aged 16-18 years, Black or African American, and Hispanic donors increased by 66%, 38%, and 9%, respectively, since 2021. Donation deferrals for travel increased since 2021 (+162%). From 2021 to 2023, the median price hospitals paid per unit of leukoreduced red blood cells, fresh frozen plasma, and leukoreduced and pathogen-reduced apheresis platelets increased. Apheresis platelets experienced the largest price increase per unit (+$65). Compared with 2021, the proportion of transfusing facilities using pathogen-reduced platelets increased in 2023 (60% vs. 64%). The overall rate of transfusion-associated adverse reactions per 100,000 components transfused was higher in 2023 than in 2021 (312.3 vs. 273.8), although the rate of transfusion-transmitted infections (bacterial, viral, and parasitic) declined in 2023 (0.25 vs. 0.43).
conclusionFrom 2021 to 2023, blood donations among older donors decreased, while donations from younger and Black or African American donors increased. Adoption of pathogen-reduced platelets and cost of all blood products increased.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.